Antigenics shares surge on data from Oncophage study
PrintDisable live quotesRSSDigg itDel.icio.usBy Gabriel Madway
Last Update: 10:50 AM ET Apr 16, 2007
SAN FRANCISCO (MarketWatch) -- Antigenics Inc. (AGEN : antigenics inc del com
News , chart , profile , more
Last: 4.57+0.90+24.52%
11:18am 04/16/2007
Delayed quote dataAdd to portfolio
Analyst
Create alertInsider
Discuss
Financials
Sponsored by:
AGEN4.57, +0.90, +24.5%) shares leapt 29% to $4.74 in Monday morning trade after the company presented updated data from a Phase 1/2 investigator-sponsored trial of Antigenics' investigational cancer vaccine Oncophage in recurrent, high-grade glioma. Preliminary results from the study showed that Oncophage vaccination was associated with significant tumor-specific immune response in all 12 treated patients from baseline. Of the 12 patients treated, four continue to receive Oncophage and eight have completed treatment, Antigencis said. Seven of the eight patients have exceeded the historical median benchmark of 6.5 months survival from time of recurrence.